ALLIANCE AND COLLABORATION AGREEMENTS (Details)	1 Months Ended								3 Months Ended							12 Months Ended				25 Months Ended
	Apr. 30, 2013 USD ($)	Jun. 30, 2012 product	Jun. 30, 2010 USD ($)	Dec. 31, 2009 USD ($)	Sep. 30, 2009 USD ($)	Mar. 31, 2009 USD ($)	Dec. 31, 2008 USD ($)	Jun. 30, 2002	Mar. 31, 2016 USD ($) product	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Mar. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Mar. 31, 2013 USD ($)	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)	Dec. 31, 2011 product	Dec. 31, 2009 payment	Mar. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)	Dec. 31, 2015 USD ($)	Mar. 31, 2012 USD ($)	Jan. 31, 2012
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Accrued profit sharing and royalty expenses									$ 38,709,000													$ 65,725,000
Research and Development Expense									19,022,000		$ 14,962,000
Teva
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone Payment, Paid									3,500,000
Tolmar Incorporated
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Maximum Loan Amount Pursuant to Loan and Security Agreement									$ 15,000,000													15,000,000	$ 15,000,000
Acceptance Of Regulatory Filings For Substantive Review
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Completion Period									2 months
Minimum | IND-enabling Animal Studies for New Development Candidate
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Completion Period									12 months
Minimum | Phase 1 Trials
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Completion Period									1 year
Minimum | Phase 2 Trials
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Completion Period									1 year
Minimum | Phase 3 Trials
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Completion Period									2 years
Minimum | Bioequivalence Studies
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Completion Period									3 months
Minimum | Preparation And Submission Of Regulatory Filings
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Completion Period									6 months
Minimum | Potential Marketing Approval One
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Completion Period									1 year
Minimum | Potential Marketing Approval Two
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Completion Period									1 year
Minimum | Tolmar Product Rights
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Finite-Lived Intangible Asset, Useful Life									5 years
Maximum | IND-enabling Animal Studies for New Development Candidate
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Completion Period									18 months
Maximum | Phase 1 Trials
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Completion Period									2 years
Maximum | Phase 2 Trials
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Completion Period									3 years
Maximum | Phase 3 Trials
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Completion Period									4 years
Maximum | Bioequivalence Studies
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Completion Period									1 year
Maximum | Preparation And Submission Of Regulatory Filings
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Completion Period									12 months
Maximum | Potential Marketing Approval One
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Completion Period									3 years
Maximum | Potential Marketing Approval Two
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Completion Period									3 years
Maximum | Tolmar Product Rights
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Finite-Lived Intangible Asset, Useful Life									12 years
Specified Threshold
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Product Sales									$ 100,000,000
Shire Laboratories Incorporated
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Accrued profit sharing and royalty expenses									4,000,000		5,800,000
Tolmar Incorporated
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Accrued profit sharing and royalty expenses									$ 24,700,000		7,500,000
Number Of Products | product		11
Collaborative Arrangement Up Front Payment																	$ 21,000,000
Tolmar Incorporated | Products Approved
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number Of Products | product									10
Tolmar Incorporated | Products in Development
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number Of Products | payment																			2
Research and Development Expense																	1,550,000
Tolmar Incorporated | Up-front Payment Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative Arrangement Up Front Payment																	21,000,000
Tolmar Incorporated | Milestone Payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative Arrangement Required Payment Net										$ 5,000,000				$ 12,000,000			1,000,000
Research and Development Expense																	1,000,000
Tolmar Incorporated | Milestone Payments | Diclofenac Sodium Gel
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative Arrangement Required Payment Net												$ 2,000,000
Teva Pharmaceutical Industries Limited
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Service Agreement Term									10 years
Pfizer Incorporated
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Service Agreement Term								15 years
Valeant Pharmaceuticals International
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number Of Products | product									5
Valeant Pharmaceuticals International | Products Approved
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number Of Products | product																		1
Valeant Pharmaceuticals International | Generic Products
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number Of Products | product									4									4
Valeant Pharmaceuticals International | Branded Advanced Form of Solodyn Product
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number Of Products | product																		1
Valeant Pharmaceuticals International | Up-front Payment Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative Arrangement Contingent Payments Received And Potentially To Be Received							$ 40,000,000
Valeant Pharmaceuticals International | Milestone Payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative Arrangement Contingent Payments Received And Potentially To Be Received				$ 2,000,000	$ 5,000,000	$ 5,000,000														$ 3,000,000
Collaborative Arrangement Maximum Contingent Payments Amount									$ 8,000,000
Valeant Pharmaceuticals International | Milestone Payment Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative Arrangement Contingent Payments Received And Potentially To Be Received																				$ 15,000,000	$ 12,000,000
Endo Pharmaceuticals Incorporation
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Gain (Loss) Related to Litigation Settlement															$ 102,049,000
Deferred Revenue Estimated Period Of Recognition									112 months
Litigation Settlement, Amount	$ 102,049,000
Endo Pharmaceuticals Incorporation | Up-front Payment Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred Revenue, Additions			$ 10,000,000
Deferred Revenue									$ 0													$ 0
Endo Pharmaceuticals Incorporation | Milestone Payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative Arrangement Maximum Contingent Payments Amount									30,000,000
Astra Zeneca
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative Arrangement Quarterly Payments Made																	$ 43,564,000
Collaborative Arrangement Copromotion Service Fee Percentage																								100.00%
Accrued Royalties									4,019,000		$ 4,025,000
DURECT Corporation
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative Arrangement Up Front Payment													$ 2,000,000
Collaborative Arrangement Maximum Contingent Payments Amount									$ 61,000,000
Other Income | Shire Laboratories Incorporated
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Gain (Loss) Related to Litigation Settlement																$ 48,000,000